Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-03-27
1997-08-26
Prior, Kimberly J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, 514181, 514182, A61K 3156
Patent
active
056611412
ABSTRACT:
The present invention provides compounds and methods of inducing a variety of therapeutic responses in a subject in need of such treatment. The method includes administering a compound of Formula (I) ##STR1## wherein R.sub.1 -R.sub.7 are as defined in the specification; and wherein said compound of Formula (I) is ethylenically unsaturated at a set of locations selected from the group consisting of (a) between C.sub.4 and C.sub.5 ; (b) both between C.sub.3 and C.sub.4 and between C.sub.5 and C.sub.6 ; (c) between C.sub.5 and C.sub.6 ; (d) both between C.sub.4 and C.sub.5 and between C.sub.6 and C.sub.7 ; (e) both between C.sub.3 and C.sub.4 between C.sub.5 and C.sub.6 and between C.sub.7 and C.sub.8 ; (f) both between C.sub.4 and C.sub.5 and between C.sub.7 and C.sub.8 ; and (g) both between C.sub.5 and C.sub.6 and between C.sub.7 and C.sub.8.
The compounds of Formula (I) are administered in an amount effective to induce the desired therapeutic response.
REFERENCES:
patent: 2661357 (1953-12-01), Huffman
patent: 3067198 (1962-12-01), Wettstein et al.
patent: 3077482 (1963-02-01), Wettstein et al.
patent: 3077486 (1963-02-01), Huffman
patent: 3729560 (1973-04-01), Hagerman
patent: 3729568 (1973-04-01), Kligman
patent: 4013762 (1977-03-01), Benson et al.
patent: 4022769 (1977-05-01), Grunwell et al.
patent: 4048159 (1977-09-01), de Ruggieri et al.
patent: 4054651 (1977-10-01), Benson et al.
patent: 4055641 (1977-10-01), Benson et al.
patent: 4071624 (1978-01-01), Grunwell et al.
patent: 4071625 (1978-01-01), Grunwell et al.
patent: 4078060 (1978-03-01), Benson et al.
patent: 4078061 (1978-03-01), Benson et al.
patent: 4087524 (1978-05-01), Grunwell et al.
patent: 4088760 (1978-05-01), Benson et al.
patent: 4096254 (1978-06-01), Benson et al.
patent: 4126693 (1978-11-01), Gander et al.
patent: 4139617 (1979-02-01), Grunwell et al.
patent: 4239681 (1980-12-01), Grunwell et al.
patent: 4317818 (1982-03-01), Benson et al.
patent: 4396615 (1983-08-01), Petrow et al.
patent: 4499021 (1985-02-01), Varma
patent: 4512986 (1985-04-01), Reel et al.
patent: 4891367 (1990-01-01), Angelastro et al.
patent: 4966897 (1990-10-01), Angelastro et al.
patent: 5108995 (1992-04-01), Casper
patent: 5124313 (1992-06-01), Schaeffer et al.
patent: 5278310 (1994-01-01), Raspanti
patent: 5494905 (1996-02-01), Hesse et al.
M.N. Mueller and A. Kappas; Estrogen Parmacology. II. Suppression of Experimental Immune Polyarthritis (29715), Estrogens Biol. Animal pp. 845-847 (1964).
R.E. Counsell et al; Chemical and Biological Properties of Some 17-Substituted Estradiol Derivatives, Journal of Medicinal Chemistry 9, pp. 689-692 (1966).
A.S. Spangler et al; Enhancement of the Anti-inflammatory Action of Hydrocortisone by Estrogen, Estrogens 29, pp. 650-655 (1969).
M.Dyson and J. Joseph; The Effects of Female Sex Hormones on Tissue Regeneration in the Rabbit's Ear, J. Endocr. 51, pp. 685-697 (1971).
R. Muller; Estrogens as additives in shampoos, Hautarzt 24, pp. 130-131 (1973).
M.N. Goodman and R.L.Hazelwood; Short-Term Effects of Oestradiol Benzoate in Normal, Hypophysectomized and Alloxan-Diabetic Male Rats, J. Endocr 62, pp. 439-449 (1974).
H. Hosoda and J. Fishman; Unusually Facile Aromatization of 2.beta.-Hydroxy-19-oxo-4-androstene-3,17-dione to Estrone. Implications in Estrogen Biosynthesis, Journal of American Chemical Society 96, pp. 7325-7329 (1974).
J.O. Johnston et al; Behavioral Effects of 19-Hydroxytestosterone; Sexual Behavior: Pharmacology and Biochemistry pp. 227-240 (1975).
C.E. Orfanos and H. Wustner; Penetration and Side Effects of Local Application of Estrogen in Androgenetic Alopecia; Hautarzt 26 pp. 367-369 (1975).
H. U. Schweikert et al; Aromatization of Androstenedione by Isolated Human Hairs, JCE & M 40, No.3, pp. 413-417 (1975).
L.A. Rigg et al; Efficacy of Intravaginal and Intranasal Administration of Micromized Estradiol-17.beta.; Journal of Clinical Endocrinology & Metabolism, 46 No. 6., pp. 1261-1264 (1977).
C.H. Phoenix; Induction of Sexual Behavior in Ovariectomized Rhesus Females with 19-Hydroxytestosterone; Hormones and Behavior 8, pp. 356-362 (1977).
R.F. Parrott;Courtship and Copulation in Prepubertally Castrated Male Sheep (Wethers) Treated with 17.beta.-Estradiol, Aromatizable Androgens, or Dihydrotestosterone; Hormones and Behavior 11 pp. 20-27 (1978).
T.A. Marks and V. Petrow; Effect of the Preestrogen 4-Androstene-3,17-dion-19-al on the Dunning R3327 Prostatic Adenocarcinoma; Cancer Research 43, pp. 3687,3690 (1983).
N. S. Latman: Relation of Menstrual Cycle Phase to Symptoms of Rheumatoid Arthritis; The American Journal of Medicine 74, pp. 957-960 (1983).
J.M. Gottswinter et al; Gynecomastia caused by estrogen containing hair lotion; J. Endocrinol. Invest 7 pp. 383-386 (1984).
L.J. Carrigton and C.J. Bailey; Effects of Natural and Synthetic Estrogens and Progestins on Glycogen Deposition in Female Mice, Hormone Res. 21, pp. 199-203 (1985).
E.H. Leitzer et al; Androgenic and Estrogenic Metabolites in Serum of Mice Fed Dehydroepiandrosterone: Relationship to Antihyperglycemic Effects, Metabolism 36 No. 9, pp. 863-869 (1987).
J. N. Wright and M. Akhtar; Studies on Estrogen Biosynthesis using Radioactive and Stable Istopes; Steroids 55, pp. 142-151 (Apr. 1990).
C.E.M. Griffiths, et al; Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: a vehicle-controlled trial; Journal of American Academy of Dermatology 30 No. 1, pp. 76-84 (1994).
A. Basdevant et al; Transdermal Estradiol, New England Journal of Medicine 315 No. 24, (1986).
LandOfFree
19-oxygenated steroids as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 19-oxygenated steroids as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 19-oxygenated steroids as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1988641